Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409993 · ClinicalTrials.gov registry record · Phase 4
Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis
A Phase 4 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT01409993 is a Phase 4 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 78 participants.
The verdict
NCT01409993, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.
Interventions
- DRUG Placebo
- DRUG Sildenafil
- DIAGNOSTIC_TEST Hyperglycemic clamp
- DIAGNOSTIC_TEST Euglycemic clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01409993
The ClinicalTrials.gov registry entry for NCT01409993 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01409993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01409993 about?
NCT01409993 is a clinical study titled "Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis". The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.
What is the current status of trial NCT01409993?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2011-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01409993?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG), Hyperglycemic clamp (DIAGNOSTIC_TEST), Euglycemic clamp (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01409993?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.